Published in Cancer Weekly, August 30th, 2005
"Fulvestrant is an estrogen receptor antagonist with no agonist effects," stated investigators at Christie Hospital, United Kingdom. "In the second-line treatment of advanced breast carcinoma, fulvestrant was shown previously to be as effective as the third-generation aromatase inhibitor, anastrozole, in terms of time to disease progression and objective response rates."
"The authors," A. Howell and colleagues, "reported the overall survival results from these studies. A prospectively planned, combined, overall survival analysis was performed, including data from two...
Want to see the full article?
Welcome to NewsRx!
Learn more about a six-week, no-risk free trial of Cancer Weekly
NewsRx also is available at LexisNexis, Gale, ProQuest, Factiva, Dialog, Thomson Reuters, NewsEdge, and Dow Jones.